The Pharmacokinetics (PK) Core is a new core in the University of Michigan Comprehensive Cancer Center (UMCCC). PK core has four objectives to support UMCCC strategic goals for next five years: Objective 1: To support preclinical pharmacokinetics (PK) for lead compound selection and dose regimen optimization, which enhances anticancer drug discovery &development for Experimental Therapeutics Program of UMCCC. Objective 2: To support clinical pharmacokinetics (PK) and optimize dose regimen of anticancer drugs In clinical studies, which supports and increase investigator-initiated clinical trials (phase I and phase II) for Translational and Clinical Research Programs of UMCCC. Objective 3: To increase grants, publications, and patent applications with UMCCC members, Objective 4;To enhance Interactions among UMCCC members for preclinical experimental and clinical developmental therapeutics. PK Core has 3000 sq ft lab space, 3.5 FTE, four LC-MS end three HPLC systems. The PK core is operated under Core Director and Advisory Committee. In the last two years during its establishment, the PK core has supported preclinical and clinical pharmacokinetics in animal models and clinical trials of 341 compounds (97% from UMCCC) from 31 investigators (76% are UMCCC members). For instance, the PK core has supported IAP Inhibitor (AT-406) development to advance lo phase I clinical studies at UMCCC. The PK core also significantly contributed Mdm2 inhibitor development with joint patents together with UMCCC members, which was licensed by Sanofl-Aventis for $360M. The pharmacokinetic studies In PK core has resulted in 20 joint grant applications, 20 manuscripts, 7 meeting abstracts, and three patents with UMCCC members in the last two years. The PK core provides significant cost effectiveness with 50% discount to UMCCC members and enhances scientific Interactions with UMCCC members. The PK core expects to spend 60% effort (compounds and required effort) for preclinical pharmacokinetics in animal models and 40% effort (compounds and required efforts) for clinical pharmacokinetics in clinical trials.
Pharmacokinetics (PK) core supports preclinical pharmacokinetics for lead compound selection in anticancer drug discovery and development, and supports clinical pharmacokinetics for clinical trials of anticancer drugs in UMCCC.
| Katz, Steven J; Ward, Kevin C; Hamilton, Ann S et al. (2018) Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer. J Clin Oncol 36:1218-1224 |
| Ulintz, Peter J; Greenson, Joel K; Wu, Rong et al. (2018) Lymph Node Metastases in Colon Cancer Are Polyclonal. Clin Cancer Res 24:2214-2224 |
| Khoriaty, Rami; Hesketh, Geoffrey G; Bernard, Amélie et al. (2018) Functions of the COPII gene paralogs SEC23A and SEC23B are interchangeable in vivo. Proc Natl Acad Sci U S A 115:E7748-E7757 |
| Xu, Shilin; Aguilar, Angelo; Xu, Tianfeng et al. (2018) Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction. Angew Chem Int Ed Engl 57:1601-1605 |
| Crespo, Joel; Wu, Ke; Li, Wei et al. (2018) Human Naive T Cells Express Functional CXCL8 and Promote Tumorigenesis. J Immunol 201:814-820 |
| Qin, Tingting; Zhang, Yanxiao; Zarins, Katie R et al. (2018) Expressed HNSCC variants by HPV-status in a well-characterized Michigan cohort. Sci Rep 8:11458 |
| Hawley, Sarah T; Li, Yun; An, Lawrence C et al. (2018) Improving Breast Cancer Surgical Treatment Decision Making: The iCanDecide Randomized Clinical Trial. J Clin Oncol 36:659-666 |
| Salami, Simpa S; Hovelson, Daniel H; Kaplan, Jeremy B et al. (2018) Transcriptomic heterogeneity in multifocal prostate cancer. JCI Insight 3: |
| Manohar, Poorni M; Beesley, Lauren J; Bellile, Emily L et al. (2018) Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer. Clin Nucl Med 43:641-647 |
| Lazarus, Jenny; Maj, Tomasz; Smith, J Joshua et al. (2018) Spatial and phenotypic immune profiling of metastatic colon cancer. JCI Insight 3: |
Showing the most recent 10 out of 1493 publications
